Atlas Trials

Hipra Scientific, S.L.U

8 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Hipra Scientific, S.L.U

RecordFirmDate
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine (NCT06181292)Hipra Scientific, S.L.U2023-11-15
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 (NCT05981846)Hipra Scientific, S.L.U2023-09-04
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age. (NCT06234956)Hipra Scientific, S.L.U2023-06-08
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. (NCT05303402)Hipra Scientific, S.L.U2022-05-12
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. (NCT05305573)Hipra Scientific, S.L.U2022-03-25
A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19. (NCT05246137)Hipra Scientific, S.L.U2022-02-03
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration. (NCT05142553)Hipra Scientific, S.L.U2021-11-16
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) (NCT05142514)Hipra Scientific, S.L.U2021-11-11

Track Hipra Scientific, S.L.U automatically

Every clearance here is in the API, with alerts when new ones post.